NSE: CLSL
CROP LIFE SCIENCE LIMITED
Sells agrochemical products, which accounted for 98.5% of segment revenue in the quarter ended September 2025, with a small agro-trade line alongside. Agro chemicals generated revenue of Rs 119.27 crore and segment EBIT of Rs 20.81 crore that quarter, while full-year agro chemicals revenue for FY26 stood at Rs 201.57 crore. Total FY26 revenue was Rs 207.17 crore, with an EBITDA margin of 9.5% and net profit of Rs 6.50 crore. Raw materials make up 78.1% of revenue, making them the dominant cost; employee costs run at 6.7% and other opex at 11.7% of revenue, while depreciation is 2.4%. Capex was 0.9% of revenue in FY26, indicating limited reinvestment. Total assets stood at Rs 207.95 crore at FY26 end. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Agro chemicals (99%), Agro trade (1%), Interest & Other Income (1%). Agrochemical manufacturer and trader, raw-material-intensive
Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 201 | 207 |
| EBITDA (ex other income) | 16 | 18 |
| margin % | 8.2 | 8.6 |
| Owners' profit | 0 | 0 |
| EPS, as reported (₹) | 3.15 | 3.79 |
| ROE % · ROCE % | 6.9 · 14.1 | 7.4 · 15.6 |
| Debt / equity (x) | 0.50 | 0.61 |
| Cash from operations | (2) | (8) |
| Capex | (4) | (2) |
Exhibit 2: Quarterly performance, last 3 quarters
| ₹ crore | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | 94 | 120 | 87 |
| Profit before tax | 4 | 4 | 5 |
| Net profit | 3 | 3 | 4 |
| EPS (₹) | 1.54 | 2.31 | 1.48 |
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Agro chemicals | 119 | 98.5 |
| Agro trade | 1 | 0.8 |
| Interest & Other Income | 1 | 0.6 |
| Total, before eliminations | 121 | 100.0 |
Exhibit 4: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 10 Oct 2026 · Two Independent Directors resign from Crop Life Science board | management changes | high | — | — |
| 10 Oct 2026 · Independent Director Mr. Devang Bhikhubhai Parekh resigns from Crop Life Science | management changes | medium | — | — |
| 10 Oct 2026 · Independent Director Mr. Harendra Sevak resigns from Crop Life Science | management changes | medium | — | — |
| 10 Oct 2026 · Board defers UAE subsidiary plan, accepts two independent director resignations | board shareholder meetings | low | — | — |
| 2 Oct 2026 · Quarterly confirmation of dematerialised shares filed with NSE | compliance | minimal | — | — |
| 26 Sept 2026 · Trading window closed from Oct 1 ahead of H2 results | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.